Treatment Information

Back

Brain – Glioblastoma Multiforme treatment details. Chemotherapy, Radiation, Biologic therapy.

Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland.

Survival: monthsCountry:Switzerland
Toxiciy Grade:4City/State/Province:Lausanne
Treatments:Chemotherapy, Radiation, Biologic therapyHospital:Centre Hospitalier Universitaire Vaudois
Drugs:Journal:Link
Date:Jun 2010

Description:

Patients:
This study involved 52 patients with newly diagnosed glioblastoma. The median age of the patients was 57 years and 62% were male. Patients had not received prior chemotherapy or radiotherapy.

Treatment:
Patients were treated with a combination of radiotherapy, the chemotherapy agent temozolomide, and a biologic agent called cilengitide, which targets cellular proteins called integrins to inhibit cancer cell signaling and growth.

Toxicities:
The most common toxicity in this study was lymphocytopenia, and 56% patients experienced grade 3 or 4. Other grade 3 or 4 toxicities included thrombocytopenia (14% of patients), headache (6%), and fatigue (4%). There were no study-related deaths reported.

Results:
Median overall survival rate in this study was 16.1 months. Median progression-free survival was 8 months.

Support:
This study was supported by Merck, the company that manufactures cilengitide.

Correspondence: Dr. Roger Stupp; email: [email protected]



Back